Mr. Miels assumed full responsibilities as CEO of GSK and joined its board on January 1, 2026, taking the helm of one of the world’s leading biopharmaceutical companies at a pivotal moment in its growth trajectory. The company anticipates total sales of more than £40 billion by 2031 and 15 major pipeline opportunities set to launch between 2025 and 2031. He joined GSK in 2017 and most recently served as chief commercial officer with worldwide responsibility for medicines and vaccines, proving instrumental in building GSK’s specialty medicines portfolio, particularly in oncology and respiratory. A highly respected and experienced global biopharma leader, Mr. Miels brings to the CEO role a breadth of senior-level experience, having previously held leadership positions at AstraZeneca, Roche and Sanofi-Aventis before joining GSK. His predecessor allowed GSK to deliver a comprehensive step-change in operating performance, portfolio and pipeline, prioritizing specialty medicines and vaccines, reinvigorating research and development, strengthening the balance sheet, and creating Haleon through the successful demerger of consumer healthcare. Mr. Miels assumed leadership of a company performing to a new standard, with a strengthened foundation and clear ambitions for long-term growth.
